Thomas Goddemeier

1.8k total citations · 1 hit paper
18 papers, 1.3k citations indexed

About

Thomas Goddemeier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Thomas Goddemeier has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Thomas Goddemeier's work include Lung Cancer Treatments and Mutations (10 papers), DNA Repair Mechanisms (5 papers) and Cancer-related Molecular Pathways (4 papers). Thomas Goddemeier is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), DNA Repair Mechanisms (5 papers) and Cancer-related Molecular Pathways (4 papers). Thomas Goddemeier collaborates with scholars based in Germany, United Kingdom and United States. Thomas Goddemeier's co-authors include Joachim von Pawel, Robert Pirker, Wilfried Eberhardt, U. Gatzemeier, Filippo de Marinis, Ihor Vynnychenko, Kenneth J. O’Byrne, Maciej Krzakowski, Chih-Teng Yu and Rodryg Ramlau and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Thomas Goddemeier

18 papers receiving 1.3k citations

Hit Papers

Cetuximab plus chemotherapy in patients with advanced non... 2009 2026 2014 2020 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    2009 1.0k citations Robert Pirker, Jose R. Pereira et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Goddemeier Germany 9 966 930 352 179 101 18 1.3k
Dana Ghiorghiu United Kingdom 15 808 0.8× 929 1.0× 497 1.4× 171 1.0× 54 0.5× 36 1.4k
Ri-Qiang Liao China 11 917 0.9× 905 1.0× 314 0.9× 286 1.6× 233 2.3× 36 1.4k
Vladimir Vladimirov United States 12 1.3k 1.3× 677 0.7× 235 0.7× 300 1.7× 124 1.2× 25 1.6k
Ira A. Oliff United States 8 1.3k 1.3× 1.2k 1.3× 451 1.3× 226 1.3× 54 0.5× 12 1.7k
Etienne Giroux‐Leprieur France 23 1.0k 1.1× 706 0.8× 492 1.4× 252 1.4× 194 1.9× 77 1.5k
Jacqui Rowbottom United Kingdom 10 1.2k 1.3× 791 0.9× 567 1.6× 321 1.8× 74 0.7× 14 1.6k
Gonzalo Recondo United States 15 637 0.7× 576 0.6× 386 1.1× 313 1.7× 103 1.0× 54 1.1k
Jaromı́r Roubec Czechia 9 1.3k 1.3× 1.3k 1.4× 574 1.6× 170 0.9× 48 0.5× 23 1.7k
Jean-Louis Pujol France 15 1.2k 1.2× 1.1k 1.2× 405 1.2× 182 1.0× 167 1.7× 20 1.7k

Countries citing papers authored by Thomas Goddemeier

Since Specialization
Citations

This map shows the geographic impact of Thomas Goddemeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Goddemeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Goddemeier more than expected).

Fields of papers citing papers by Thomas Goddemeier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Goddemeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Goddemeier. The network helps show where Thomas Goddemeier may publish in the future.

Co-authorship network of co-authors of Thomas Goddemeier

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Goddemeier. A scholar is included among the top collaborators of Thomas Goddemeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Goddemeier. Thomas Goddemeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Burris, Howard A., Jordan Berlin, Hendrik‐Tobias Arkenau, et al.. (2024). A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. British Journal of Cancer. 130(7). 1131–1140. 20 indexed citations
2.
Mozgunov, Pavel, Thomas Jaki, Ioannis Gounaris, et al.. (2022). Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial. Statistics in Medicine. 41(30). 5789–5809. 5 indexed citations
3.
Telli, Melinda L., Sara M. Tolaney, Geoffrey I. Shapiro, et al.. (2022). Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. npj Breast Cancer. 8(1). 45–45. 31 indexed citations
4.
Plummer, Ruth, Emma Dean, Hendrik‐Tobias Arkenau, et al.. (2021). A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 163. 19–26. 26 indexed citations
5.
Yap, Timothy A., Anthony W. Tolcher, Elizabeth Ruth Plummer, et al.. (2021). A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.. Journal of Clinical Oncology. 39(15_suppl). TPS3153–TPS3153. 12 indexed citations
6.
Kojima, Takashi, Kentaro Yamazaki, Ken Kato, et al.. (2018). Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors. Cancer Science. 109(10). 3253–3262. 15 indexed citations
7.
Plummer, Ruth, Natalie Cook, Tobias Arkenau, et al.. (2018). Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii519–viii519. 2 indexed citations
8.
Plummer, Elizabeth Ruth, Natalie Cook, Hendrik‐Tobias Arkenau, et al.. (2018). Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). e21048–e21048. 4 indexed citations
9.
Triest, Baukelien van, Lars Damstrup, Volker Budach, et al.. (2017). A phase Ia/Ib trial of the DNA-dependent protein kinase inhibitor (DNA-PKi) M3814 in combination with radiotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). e14048–e14048. 5 indexed citations
10.
Kato, Ken, Takashi Kojima, Kentaro Yamazaki, et al.. (2016). Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2522–2522. 1 indexed citations
11.
12.
13.
Pirker, Robert, J. R. Pereira, Aleksandra Szczęsna, et al.. (2012). Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer. 77(2). 376–382. 5 indexed citations
14.
Machiels, J-P., Marie‐Christine Kaminsky, Ulrich Keller, et al.. (2012). Phase IB Trial of Imo-2055 in Combination with 5-Fu, Cisplatin and Cetuximab in 1st-Line PTS with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN). Annals of Oncology. 23. ix342–ix342. 1 indexed citations
15.
16.
17.
Pirker, Robert, Jose R. Pereira, Aleksandra Szczęsna, et al.. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet. 373(9674). 1525–1531. 1046 indexed citations breakdown →
18.
Schmitt, Michael, et al.. (2006). Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs. European Journal of Pharmacology. 554(1). 46–52. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dana Ghiorghiu Breakdown of academic impact, for papers by Ri-Qiang Liao Breakdown of academic impact, for papers by Vladimir Vladimirov Breakdown of academic impact, for papers by Ira A. Oliff Breakdown of academic impact, for papers by Etienne Giroux‐Leprieur Breakdown of academic impact, for papers by Jacqui Rowbottom Breakdown of academic impact, for papers by Gonzalo Recondo Breakdown of academic impact, for papers by Jaromı́r Roubec Breakdown of academic impact, for papers by Jean-Louis Pujol
Rankless by CCL
2026